Abcuro
Yajun Xu is currently president of Hongsen Investment Group. She also serves as Sr. Advisor for Shangbay Capital, co-founder of Epimab Inc., and board member and advisor on numerous biotech companies in U.S. and China. Previously, she was Sr. Vice President of corporate development at Shangpharma, Executive Vice President of biology and pre-clinical service at Chempartner in Shanghai, China. Prior to Joining Shangpharma, Yajun was director of inflammation at Millennium pharma Inc. and senior scientist at BASF Bioresearch Corp. (now AbbVie Bioresearch Corp.). She received her Ph.D. in Biochemistry at Brandeis University and postdoctoral training at Harvard School of Public Health.
This person is not in the org chart
This person is not in any offices
Abcuro
2 followers
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies.